GC
RXRX icon

Guggenheim Capital’s Recursion Pharmaceuticals RXRX Stock Holding History

Guggenheim Capital’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$899K Sell
245,051
-1,655
-0.7% -$5.51K 0.01% 1067
2026
Q1 		$757K Buy
246,706
+63,259
+34% +$244K 0.01% 1076
2025
Q4 		$750K Buy
183,447
+57,453
+46% +$285K 0.01% 1080
2025
Q3 		$615K Buy
125,994
+2,934
+2% +$15.4K ﹤0.01% 1099
2025
Q2 		$623K Sell
123,060
-23,479
-16% -$115K ﹤0.01% 1070
2025
Q1 		$775K Buy
146,539
+3,482
+2% +$25.4K 0.01% 990
2024
Q4 		$967K Sell
143,057
-12,173
-8% -$81.8K 0.01% 935
2024
Q3 		$1.02M Buy
155,230
+31,724
+26% +$227K 0.01% 1091
2024
Q2 		$926K Buy
123,506
+81,325
+193% +$709K 0.01% 1161
2024
Q1 		$421K Sell
42,181
-1,592
-4% -$17.7K ﹤0.01% 1540
2023
Q4 		$432K Sell
43,773
-158
-0.4% -$1.13K ﹤0.01% 1513
2023
Q3 		$336K Buy
43,931
+27,119
+161% +$271K ﹤0.01% 1588
2023
Q2 		$126K Buy
+16,812
New +$118K ﹤0.01% 1819

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Guggenheim Capital's RXRX Position: Q2 2026 in Review

Guggenheim Capital reduced its Recursion Pharmaceuticals (RXRX) stake by 0.67% in Q2 2026, selling an estimated $5.51K and leaving 245,051 shares worth $899K. The position accounts for 0.01% of the portfolio, ranked #1067.

Guggenheim Capital first reported a position in RXRX in Q2 2023 and has held it in 13 quarters since. The position peaked at $1.02M in Q3 2024. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Guggenheim Capital held 245,051 shares of Recursion Pharmaceuticals worth $899K as of Q2 2026.
  • Guggenheim Capital sold 1,655 Recursion Pharmaceuticals shares in Q2 2026, an estimated $5.51K.
  • Recursion Pharmaceuticals made up 0.01% of Guggenheim Capital's portfolio in Q2 2026, its #1067 holding.
  • Guggenheim Capital first reported a position in Recursion Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • Guggenheim Capital's Recursion Pharmaceuticals position peaked at $1.02M in Q3 2024.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.